Biogen Inc (BIIB)

284.75
NASDAQ : Health Care
Prev Close 284.75
Day Low/High 0.00 / 0.00
52 Wk Low/High 223.02 / 333.65
Avg Volume 1.94M
Exchange NASDAQ
Shares Outstanding 215.95M
Market Cap 62.11B
EPS 17.00
P/E Ratio 16.99
Div & Yield N.A. (N.A)

Latest News

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.

Biogen To Present At The 2017 RBC Capital Markets Global Healthcare Conference

Biogen To Present At The 2017 RBC Capital Markets Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 2017 RBC Capital Markets Global Healthcare Conference.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Biogen To Present At The Leerink Partners 6th Annual Global Healthcare Conference

Biogen To Present At The Leerink Partners 6th Annual Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 6 th Annual Global Healthcare Conference.

Analysts' Actions -- Apple, Biogen, Caterpillar, Micron and More

Analysts' Actions -- Apple, Biogen, Caterpillar, Micron and More

Here are Tuesday's top research calls, including upgrades for Biogen and Caterpillar, and increased price targets for Apple and Micron.

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Biogen Reveals Federal Investigation Into Pricing, Rebate Payments

Biogen Reveals Federal Investigation Into Pricing, Rebate Payments

The biotech disclosed subpoenas in a regulatory filing.

There Is So Little Attention Paid to the Fed Meeting

There Is So Little Attention Paid to the Fed Meeting

The Fed is simply not a market catalyst this time.

Biogen Completes Separation Of Global Hemophilia Business, Bioverativ

Biogen Completes Separation Of Global Hemophilia Business, Bioverativ

Biogen Inc. (NASDAQ: BIIB) today announced the completion on February 1, 2017 of the separation of its global hemophilia business.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Alphabet's Verily Sells Stake to Temasek in Bid for Overseas Expansion

Alphabet's Verily Sells Stake to Temasek in Bid for Overseas Expansion

The sale of the $800M stake to Temasek comes as the Google parent scales back some of its other big bets.

Dow Scores Another Record but S&P 500, Nasdaq Decline

Dow Scores Another Record but S&P 500, Nasdaq Decline

The Dow Jones Industrial Average scores a record close for its second day in a row, benefiting from a small bump that cemented its position above 20,000.

Dow Set for a Fresh Record as DuPont Provides a Bump

Dow Set for a Fresh Record as DuPont Provides a Bump

The Dow Jones Industrial Average is on track to squeeze out another record close, its second in a row, in a mixed session.

Biogen Rallies Despite Mixed Revenue Guidance

Biogen Rallies Despite Mixed Revenue Guidance

For 2017 to work, Biogen needs a successful commercial launch of Spinraza, the newly approved treatment for spinal muscular atrophy, a rare and fatal disease that strikes kids.

Stocks Hold Mixed as Record-Breaking Rally Pauses

Stocks Hold Mixed as Record-Breaking Rally Pauses

Stocks hold mixed on Thursday as markets run out of steam to push a record-breaking rally into day two.

Stock Futures Turn Mixed as Wall Street Pauses After Historic Rally

Stock Futures Turn Mixed as Wall Street Pauses After Historic Rally

Stock futures turn mixed on Thursday as investors take pause after Wednesday's history-making rally.

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

McKesson, Bristol-Myers and Varian were having a busy morning.

Biogen Reports 2016 Revenues Of $11.4 Billion

Biogen Reports 2016 Revenues Of $11.4 Billion

Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2016 financial results, including: Full year total revenues of $11.

5 Reasons Why Celgene Should Buy Competitor Biogen

5 Reasons Why Celgene Should Buy Competitor Biogen

There are several reasons why Celgene should buy Biogen.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

A merger would be smart, profitable ... and attention-grabbing.

Biogen Resolves Multiple Sclerosis Drug Dispute

Biogen Resolves Multiple Sclerosis Drug Dispute

Shares of Biogen were lower Tuesday after the company resolved a dispute with Forward Pharma over its multiple sclerosis drug.

Biogen Fourth Quarter And Year End 2016 Financial Results Webcast Adjusted To 8:00 Am On January 26, 2017

Biogen Fourth Quarter And Year End 2016 Financial Results Webcast Adjusted To 8:00 Am On January 26, 2017

Please note: the start time of the webcast has moved to 8:00 am ET.

Forward Pharma Shares Jump on Biogen License Agreement

Forward Pharma Shares Jump on Biogen License Agreement

Biogen will pay Forward $1.25 billion.

Siemens Healthineers And Biogen Announce Agreement To Jointly Develop New MRI Tools For Multiple Sclerosis

Siemens Healthineers And Biogen Announce Agreement To Jointly Develop New MRI Tools For Multiple Sclerosis

Siemens Healthineers and Biogen have announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity...

Biogen And Forward Pharma Agree To Enter Into Settlement And License Agreement

Biogen And Forward Pharma Agree To Enter Into Settlement And License Agreement

Biogen Inc. (NASDAQ: BIIB) today announced that it has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma's shareholders and other customary...